=================================================================
STOMACH ADENOCARCINOMA
FALSE ATTRACTOR ANALYSIS — SCRIPT 1
Dataset: GSE66229
Framework: OrganismCore
Doc: pre-STAD | Date: 2026-03-01
=================================================================

  PREDICTIONS LOCKED:
  Switch: CLDN18/MUC5AC/TFF1/GKN1 DOWN
  FA:     CDX2/MUC2/KRT20/VIM UP
  Lock:   EZH2 UP (5th cancer)
  Find:   ERBB2/HER2 elevated
  Switch: MUC5AC→MUC2 identity

=== STEP 0: DOWNLOAD ===
=================================================================
STEP 0: DATA ACQUISITION
Dataset: GSE66229
  Gastric adenocarcinoma
  Affymetrix GPL570
  Korean cohort
=================================================================
  Found: GSE66229_series_matrix.txt.gz (113.3 MB) — reusing

=== STEP 1: PARSE MATRIX ===

  Parsing: GSE66229_series_matrix.txt.gz
  Data lines: 54675
  Samples: 400
  Raw shape: (54675, 400)
  Sample IDs (first 4): ['GSM1523727', 'GSM1523728', 'GSM1523729', 'GSM1523730']
  Meta shape: (400, 30)
  Meta cols: ['title', 'geo_accession', 'status', 'submission_date', 'last_update_date', 'type', 'channel_count', 'source_name_ch1', 'organism_ch1', 'characteristics_ch1']
  Meta sample values:
    [title]: ['T107', 'T108', 'T109']
    [geo_accession]: ['GSM1523727', 'GSM1523728', 'GSM1523729']
    [status]: ['Public on Apr 17 2015', 'Public on Apr 17 2015', 'Public on Apr 17 2015']
    [submission_date]: ['Oct 10 2014', 'Oct 10 2014', 'Oct 10 2014']
    [last_update_date]: ['Apr 17 2015', 'Apr 17 2015', 'Apr 17 2015']
    [type]: ['RNA', 'RNA', 'RNA']
    [channel_count]: ['1', '1', '1']
    [source_name_ch1]: ['Tumor from patient 107', 'Tumor from patient 108', 'Tumor from patient 109']

=== STEP 2: NORMALIZE ===

  Normalizing (54675, 400)...
  Normalized: (54675, 400)

=== STEP 3: PROBE MAPPING ===

--- Probe mapping (GPL570) ---
  Probes: 54675
  Sample: ['1007_s_at', '1053_at', '117_at', '121_at', '1255_g_at']
  Trying annotation: https://ftp.ncbi.nlm.nih.gov/geo/platforms/GPL570nnn/GPL570/annot/GPL570.annot.gz
  Failed: HTTP Error 404: Not Found
  Trying annotation: https://ftp.ncbi.nlm.nih.gov/geo/platforms/GPL570nnn/GPL570/soft/GPL570.soft.gz
  Failed: HTTP Error 404: Not Found
  Using hard-coded target probe map...
  Hard-coded genes: 59
  Genes: ['ATP4A', 'AURKA', 'BMI1', 'BUB1B', 'CCNB1', 'CCND1', 'CD163', 'CD274', 'CD68', 'CD8A', 'CDC20', 'CDH1', 'CDH2', 'CDK4', 'CDK6', 'CDX2', 'CHGA', 'DNMT3A', 'EGFR', 'ENO2', 'ERBB2', 'ERBB3', 'ERBB4', 'EZH2', 'FABP1', 'FGFR2', 'FN1', 'FOXP3', 'GKN2', 'GRB7', 'HDAC1', 'KDM6A', 'KRAS', 'MET', 'MKI67', 'MMP2', 'MMP9', 'MUC2', 'MUC5AC', 'MUC6', 'MYC', 'NCAM1', 'OLFM4', 'PCNA', 'PDCD1', 'PGC', 'PLK1', 'RB1', 'SNAI1', 'SNAI2', 'TFF1', 'TFF2', 'TOP2A', 'TP53', 'TWIST1', 'VIL1', 'VIM', 'ZEB1', 'ZEB2']
  Total mapped: 64
  Gene matrix: 59 genes
  Target genes: 59/72
  Missing: ['CLDN18', 'GKN1', 'KRT20', 'EED', 'SUZ12', 'DNMT3B', 'HDAC2', 'PTEN', 'SI', 'LCT', 'FABP2', 'CD4', 'SYP']
  Saved: gene_matrix.csv

=== STEP 4: CLASSIFY ===

--- Classifying samples ---
  Total samples: 400

  ALL META COLUMNS:
  [title]: ['T107', 'T108', 'T109', 'N132']
  [geo_accession]: ['GSM1523727', 'GSM1523728', 'GSM1523729', 'GSM1523730']
  [status]: ['Public on Apr 17 2015', 'Public on Apr 17 2015', 'Public on Apr 17 2015', 'Public on Feb 15 2019']
  [submission_date]: ['Oct 10 2014', 'Oct 10 2014', 'Oct 10 2014', 'Oct 10 2014']
  [last_update_date]: ['Apr 17 2015', 'Apr 17 2015', 'Apr 17 2015', 'Feb 15 2019']
  [type]: ['RNA', 'RNA', 'RNA', 'RNA']
  [channel_count]: ['1', '1', '1', '1']
  [source_name_ch1]: ['Tumor from patient 107', 'Tumor from patient 108', 'Tumor from patient 109', 'Normal from patient 132']
  [organism_ch1]: ['Homo sapiens', 'Homo sapiens', 'Homo sapiens', 'Homo sapiens']
  [characteristics_ch1]: ['tissue: Gastric tumor', 'tissue: Gastric tumor', 'tissue: Gastric tumor', 'tissue: normal gastric tissue']
  [molecule_ch1]: ['total RNA', 'total RNA', 'total RNA', 'total RNA']
  [extract_protocol_ch1]: ['Samples are processed in parallel in 96-well plates to minimize potential variation. Reaction purification is achieved using magnetic binding beads for cDNA and Qiagen RNeasy kits for cRNA purification.', 'Samples are processed in parallel in 96-well plates to minimize potential variation. Reaction purification is achieved using magnetic binding beads for cDNA and Qiagen RNeasy kits for cRNA purification.', 'Samples are processed in parallel in 96-well plates to minimize potential variation. Reaction purification is achieved using magnetic binding beads for cDNA and Qiagen RNeasy kits for cRNA purification.', 'Samples are processed in parallel in 96-well plates to minimize potential variation. Reaction purification is achieved using magnetic binding beads for cDNA and Qiagen RNeasy kits for cRNA purification.']
  [label_ch1]: ['biotin', 'biotin', 'biotin', 'biotin']
  [label_protocol_ch1]: ['standard Affymetrix protocol', 'standard Affymetrix protocol', 'standard Affymetrix protocol', 'standard Affymetrix protocol']
  [taxid_ch1]: ['9606', '9606', '9606', '9606']
  [hyb_protocol]: ['GeneChip microarrays are loaded with the fragmented target sample/hybridization buffer mix using standard manual techniques. Arrays are hybridized for 18 hours at 45oC with vigorous mixing. Unbound sample is removed and staining is accomplished through the binding of streptavidin conjugated phycoerythrin to the hybridized target. Excess label is removed. Washing and staining steps are performed by the Affymetrix FS450 fluidics station using standard protocols.', 'GeneChip microarrays are loaded with the fragmented target sample/hybridization buffer mix using standard manual techniques. Arrays are hybridized for 18 hours at 45oC with vigorous mixing. Unbound sample is removed and staining is accomplished through the binding of streptavidin conjugated phycoerythrin to the hybridized target. Excess label is removed. Washing and staining steps are performed by the Affymetrix FS450 fluidics station using standard protocols.', 'GeneChip microarrays are loaded with the fragmented target sample/hybridization buffer mix using standard manual techniques. Arrays are hybridized for 18 hours at 45oC with vigorous mixing. Unbound sample is removed and staining is accomplished through the binding of streptavidin conjugated phycoerythrin to the hybridized target. Excess label is removed. Washing and staining steps are performed by the Affymetrix FS450 fluidics station using standard protocols.', 'GeneChip microarrays are loaded with the fragmented target sample/hybridization buffer mix using standard manual techniques. Arrays are hybridized for 18 hours at 45oC with vigorous mixing. Unbound sample is removed and staining is accomplished through the binding of streptavidin conjugated phycoerythrin to the hybridized target. Excess label is removed. Washing and staining steps are performed by the Affymetrix FS450 fluidics station using standard protocols.']
  [scan_protocol]: ['Arrays are scanned using a GeneChip Scanner 3000 7G with a 48 array autoloader. The scanner maintains the optimal temperature for the arrays prior to and during scanning.', 'Arrays are scanned using a GeneChip Scanner 3000 7G with a 48 array autoloader. The scanner maintains the optimal temperature for the arrays prior to and during scanning.', 'Arrays are scanned using a GeneChip Scanner 3000 7G with a 48 array autoloader. The scanner maintains the optimal temperature for the arrays prior to and during scanning.', 'Arrays are scanned using a GeneChip Scanner 3000 7G with a 48 array autoloader. The scanner maintains the optimal temperature for the arrays prior to and during scanning.']
  [description]: ['ACRG Gastric cohort: microarray profiles from 300 gastric tumors and 100 patient matched normal tissue from gastric cancer patients', 'ACRG Gastric cohort: microarray profiles from 300 gastric tumors and 100 patient matched normal tissue from gastric cancer patients', 'ACRG Gastric cohort: microarray profiles from 300 gastric tumors and 100 patient matched normal tissue from gastric cancer patients', 'ACRG Gastric cohort: microarray profiles from 300 gastric tumors and 100 patient matched normal tissue from gastric cancer patients']
  [data_processing]: ['The data were analyzed by RMA with Affymetrix Power Tools package using Affymetrix default analysis settings.', 'The data were analyzed by RMA with Affymetrix Power Tools package using Affymetrix default analysis settings.', 'The data were analyzed by RMA with Affymetrix Power Tools package using Affymetrix default analysis settings.', 'The data were analyzed by RMA with Affymetrix Power Tools package using Affymetrix default analysis settings.']
  [platform_id]: ['GPL570', 'GPL570', 'GPL570', 'GPL570']
  [contact_name]: ['Michael,,Nebozhyn', 'Michael,,Nebozhyn', 'Michael,,Nebozhyn', 'Michael,,Nebozhyn']
  [contact_department]: ['GpGx/Computational System biology', 'GpGx/Computational System biology', 'GpGx/Computational System biology', 'GpGx/Computational System biology']
  [contact_institute]: ['Merck, Inc', 'Merck, Inc', 'Merck, Inc', 'Merck, Inc']
  [contact_address]: ['Mail Stop WP53B-120, 770 Sumneytown Pike, Building 53, P.O. Box 4', 'Mail Stop WP53B-120, 770 Sumneytown Pike, Building 53, P.O. Box 4', 'Mail Stop WP53B-120, 770 Sumneytown Pike, Building 53, P.O. Box 4', 'Mail Stop WP53B-120, 770 Sumneytown Pike, Building 53, P.O. Box 4']
  [contact_city]: ['West Point', 'West Point', 'West Point', 'West Point']
  [contact_state]: ['PA', 'PA', 'PA', 'PA']
  [contact_zip/postal_code]: ['19486', '19486', '19486', '19486']
  [contact_country]: ['USA', 'USA', 'USA', 'USA']
  [supplementary_file]: ['ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1523nnn/GSM1523727/suppl/GSM1523727_INT201201-10-1_107T_HG-U133_Plus_2_.CEL.gz', 'ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1523nnn/GSM1523728/suppl/GSM1523728_INT201201-10-1_108T_HG-U133_Plus_2_.CEL.gz', 'ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1523nnn/GSM1523729/suppl/GSM1523729_INT201201-10-1_109T_HG-U133_Plus_2_.CEL.gz', 'ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1523nnn/GSM1523730/suppl/GSM1523730_INT201201-10-1_132N_HG-U133_Plus_2_.CEL.gz']
  [data_row_count]: ['54675', '54675', '54675', '54675']
  Using col 'source_name_ch1': T=300 N=100

  TUMOR  : 300
  NORMAL : 100
  UNKNOWN: 0

  Final: TUMOR=300 NORMAL=100

=== STEP 5: SADDLE POINT ===

=================================================================
STEP 5: SADDLE POINT ANALYSIS
STAD TUMOR vs NORMAL GASTRIC MUCOSA
=================================================================
  TUMOR  : 300
  NORMAL : 100

  PREDICTIONS:
  DOWN: CLDN18/MUC5AC/TFF1/GKN1/CDH1
  UP:   CDX2/MUC2/KRT20/VIM/CDH2
  LOCK: EZH2 (5th cancer)
  FIND: ERBB2 elevated

  Gene       Role           Normal     Tumor    Change  p-value
  --------------------------------------------------------------------
  MUC5AC     GASTRIC        0.7690    0.7649     -0.5%  p=0.4869  ns
  TFF1       GASTRIC        0.9396    1.1395    +21.3%  p=5.72e-40 ***
  GKN2       GASTRIC        1.2782    1.3012     +1.8%  p=9.53e-04 ***
  CDH1       EMT            1.6493    1.8000     +9.1%  p=5.65e-03  **
  OLFM4      GASTRIC        0.9505    0.9599     +1.0%  p=0.1146  ns
  ATP4A      GASTRIC        1.5525    1.6694     +7.5%  p=3.30e-04 ***
  PGC        GASTRIC        1.3415    1.3610     +1.5%  p=0.0454   *
  TFF2       GASTRIC        0.4947    0.5514    +11.5%  p=3.10e-09 ***
  MUC6       GASTRIC        0.6843    0.7559    +10.5%  p=2.96e-04 ***
  CDX2       INTESTINAL     0.8686    1.0695    +23.1%  p=3.34e-22 ***
  MUC2       INTESTINAL     0.3611    0.3326     -7.9%  p=8.84e-04 ***
  VIM        EMT            1.8884    1.8193     -3.7%  p=2.22e-11 ***
  CDH2       EMT            0.7783    0.4604    -40.8%  p=9.45e-30 ***
  TWIST1     EMT            1.3098    1.0073    -23.1%  p=7.26e-23 ***
  ZEB1       EMT            1.4299    1.5024     +5.1%  p=2.67e-11 ***
  SNAI1      EMT            0.8029    0.8885    +10.7%  p=1.65e-11 ***
  SNAI2      EMT            1.2596    1.2130     -3.7%  p=0.0528  ns
  FN1        EMT            0.9441    0.9719     +2.9%  p=0.0299   *
  EZH2       EPIGEN         1.2043    1.0469    -13.1%  p=2.50e-33 ***
  BMI1       EPIGEN         1.3639    1.3074     -4.1%  p=5.19e-09 ***
  KDM6A      EPIGEN         1.0114    1.0807     +6.9%  p=8.64e-15 ***
  DNMT3A     EPIGEN         1.5841    1.4235    -10.1%  p=3.22e-12 ***
  HDAC1      EPIGEN         1.0773    1.2147    +12.8%  p=3.21e-23 ***
  MYC        SCAFFOLD       1.5659    1.6006     +2.2%  p=3.52e-04 ***
  ERBB2      HER2           1.2847    1.3972     +8.8%  p=5.61e-13 ***
  EGFR       HER2           1.1052    1.0397     -5.9%  p=7.23e-05 ***
  FGFR2      SCAFFOLD       1.3327    1.2352     -7.3%  p=3.99e-03  **
  MET        SCAFFOLD       1.4866    1.6524    +11.2%  p=1.08e-30 ***
  CCND1      SCAFFOLD       1.2730    1.3831     +8.6%  p=3.76e-13 ***
  CDK4       SCAFFOLD       1.0348    1.2370    +19.5%  p=8.22e-37 ***
  CDK6       SCAFFOLD       1.3746    1.6291    +18.5%  p=1.28e-36 ***
  RB1        SCAFFOLD       1.3157    1.4095     +7.1%  p=1.79e-16 ***
  TP53       SCAFFOLD       0.5764    0.7117    +23.5%  p=2.05e-12 ***
  KRAS       SCAFFOLD       0.9542    0.9616     +0.8%  p=0.2578  ns
  VIL1       INTESTINAL     1.3340    1.3079     -1.9%  p=0.0568  ns
  FABP1      INTESTINAL     1.4917    1.3732     -7.9%  p=7.07e-12 ***
  ZEB2       EMT            1.1229    1.4764    +31.5%  p=1.76e-38 ***
  MMP2       EMT            1.8164    1.8039     -0.7%  p=1.57e-04 ***
  MMP9       EMT            1.0480    1.3302    +26.9%  p=2.41e-25 ***
  MKI67      PROLIF         0.5523    0.8572    +55.2%  p=6.18e-31 ***
  PCNA       PROLIF         1.5836    1.7409     +9.9%  p=1.22e-36 ***
  TOP2A      PROLIF         1.1534    1.5693    +36.1%  p=1.63e-38 ***
  AURKA      PROLIF         1.0826    1.4445    +33.4%  p=1.28e-37 ***
  PLK1       PROLIF         0.5878    0.7015    +19.3%  p=7.19e-23 ***
  CCNB1      PROLIF         1.1400    1.5021    +31.8%  p=1.64e-34 ***
  CDC20      PROLIF         1.2727    1.6167    +27.0%  p=6.91e-36 ***
  BUB1B      PROLIF         1.6576    1.6368     -1.3%  p=2.70e-06 ***
  ERBB3      HER2           0.3006    0.0380    -87.4%  p=1.01e-28 ***
  GRB7       HER2           0.8493    0.7897     -7.0%  p=6.98e-05 ***
  ERBB4      HER2           0.9023    0.4822    -46.6%  p=7.75e-42 ***
  CD274      IMMUNE         0.4414    0.4540     +2.9%  p=0.0147   *
  PDCD1      IMMUNE         0.9229    0.8991     -2.6%  p=4.07e-04 ***
  CD8A       IMMUNE         1.1458    1.0821     -5.6%  p=6.26e-03  **
  FOXP3      IMMUNE         0.8787    0.8141     -7.4%  p=2.33e-08 ***
  CD68       IMMUNE         0.8107    0.9017    +11.2%  p=7.82e-13 ***
  CD163      IMMUNE         1.2096    1.3018     +7.6%  p=1.43e-15 ***
  CHGA       NE             0.5432    0.5340     -1.7%  p=0.1495  ns
  ENO2       NE             0.9048    0.8261     -8.7%  p=4.67e-03  **
  NCAM1      NE             1.3783    1.3785     +0.0%  p=0.4440  ns

  Saved: saddle_results.csv

  IDENTITY SWITCH CHECK:
    MUC5AC     N:0.7690 T:0.7649 -0.5%
    TFF1       N:0.9396 T:1.1395 +21.3%
    CDX2       N:0.8686 T:1.0695 +23.1%
    MUC2       N:0.3611 T:0.3326 -7.9%

=== STEP 6: DEPTH SCORING ===

=================================================================
STEP 6: BLOCK DEPTH SCORING
=================================================================
  Switch genes: ['MUC5AC', 'TFF1', 'GKN2', 'CDH1', 'OLFM4', 'ATP4A', 'PGC', 'TFF2', 'MUC6']
  FA markers  : ['CDX2', 'MUC2', 'VIM', 'CDH2', 'TWIST1', 'ZEB1', 'SNAI1', 'SNAI2', 'FN1']

  Block depth (300 tumors):
    Mean  : 0.4884
    Median: 0.4855
    Std   : 0.1114
    Min   : 0.0700
    Max   : 0.8325

  Top depth correlations (top 20):
  Gene              r  p-value         Role
  --------------------------------------------------
  TWIST1      +0.6341  p=3.75e-35 ***  EMT
  ZEB2        -0.5367  p=8.75e-24 ***  EMT
  AURKA       -0.5327  p=2.18e-23 ***  PROLIF
  CDC20       -0.5167  p=7.07e-22 ***  PROLIF
  CDH2        +0.4948  p=6.23e-20 ***  EMT
  CCNB1       -0.4897  p=1.67e-19 ***  PROLIF
  CDK6        -0.4762  p=2.19e-18 ***  SCAFFOLD
  MUC6        -0.4711  p=5.57e-18 ***  GASTRIC
  ERBB4       +0.4638  p=2.08e-17 ***  HER2
  TOP2A       -0.4502  p=2.24e-16 ***  PROLIF
  PCNA        -0.4183  p=3.89e-14 ***  PROLIF
  FABP1       +0.4152  p=6.25e-14 ***  INTESTINAL
  DNMT3A      +0.4115  p=1.09e-13 ***  EPIGEN
  VIM         +0.4108  p=1.21e-13 ***  EMT
  MKI67       -0.3933  p=1.54e-12 ***  PROLIF
  ATP4A       -0.3848  p=5.01e-12 ***  GASTRIC
  CDK4        -0.3744  p=2.03e-11 ***  SCAFFOLD
  CDH1        -0.3698  p=3.71e-11 ***  EMT
  SNAI2       +0.3678  p=4.82e-11 ***  EMT
  TFF1        -0.3495  p=4.79e-10 ***  GASTRIC

=== STEP 7: EZH2 ===

=================================================================
STEP 7: EZH2 ANALYSIS
5th solid cancer prediction
r(EZH2, depth) > 0 predicted
=================================================================

  EZH2 normal: 1.2043 ± 0.0758
  EZH2 tumor : 1.0469 ± 0.0996
  Change     : -13.1%
  p (tumor > normal): p=1.0000  ns
  EZH2 elevated: NOT CONFIRMED

  r(EZH2, depth) = +0.3326 p=3.52e-09
  r > 0 predicted: CONFIRMED

  Cross-cancer EZH2 pattern:
  BRCA: elevated ✓
  PAAD: elevated ✓  r>0 ✓
  PRAD: elevated ✓  r>0 ✓
  STAD: not confirmed  r>0 ✓

=== STEP 8: ERBB2/HER2 ===

=================================================================
STEP 8: ERBB2/HER2 ANALYSIS
Must find from geometry alone
Trastuzumab = standard of care ~20%
=================================================================

  Gene        Normal     Tumor    Change  p
  ----------------------------------------------------
  ERBB2       1.2847    1.3972     +8.8%  p=5.61e-13 ***
  GRB7        0.8493    0.7897     -7.0%  p=0.9999  ns
  EGFR        1.1052    1.0397     -5.9%  p=0.9999  ns
  FGFR2       1.3327    1.2352     -7.3%  p=0.9960  ns
  MET         1.4866    1.6524    +11.2%  p=1.08e-30 ***
  ERBB3       0.3006    0.0380    -87.4%  p=1.0000  ns
  ERBB4       0.9023    0.4822    -46.6%  p=1.0000  ns

  ERBB2 bimodal check:
    Range: 0.991 – 2.013
    KDE minima: 2
    Threshold : 1.7085
    HER2-high : 18 (6.0%)
    HER2-low  : 282
    Expected  : ~20%

    Depth by HER2:
      HER2-high: 0.4651 ± 0.0957
      HER2-low : 0.4899 �� 0.1123
      p=0.3676

=== STEP 9: IDENTITY SWITCH ===

=================================================================
STEP 9: GASTRIC→INTESTINAL SWITCH
MUC5AC → MUC2 | CLDN18 → CDX2
=================================================================

  Gastric (7):
  Gene          Normal     Tumor Change
  ----------------------------------------
  MUC5AC        0.7690    0.7649     -0.5%
  TFF1          0.9396    1.1395    +21.3%
  GKN2          1.2782    1.3012     +1.8%
  ATP4A         1.5525    1.6694     +7.5%
  PGC           1.3415    1.3610     +1.5%
  TFF2          0.4947    0.5514    +11.5%
  MUC6          0.6843    0.7559    +10.5%

  Intestinal (4):
  Gene          Normal     Tumor Change
  ----------------------------------------
  CDX2          0.8686    1.0695    +23.1%
  MUC2          0.3611    0.3326     -7.9%
  VIL1          1.3340    1.3079     -1.9%
  FABP1         1.4917    1.3732     -7.9%

  Identity composite:
    Gastric    N:1.0085 T:1.0776 (+6.8%)
    Intestinal N:1.0139 T:1.0208 (+0.7%)

  VERDICT: Intestinal gain confirmed — gastric loss not confirmed

=== STEP 10: FIGURE ===

--- Generating figure ---

  Figure saved: ./stad_false_attractor/results/stad_false_attractor.png